A first-in-human, Phase 1 trial assessing the safety and immunogenicity of an investigational nanoparticle influenza vaccine designed to provide long-lasting...
Maryland
RADx efforts seek to create capacity for 6 million daily tests by the end of 2020, address underserved populations. In...
A new study has begun recruiting at the National Institutes of Health in Bethesda, Maryland, to determine how many adults...
Inaugural symposium highlights collaboration in allergic, immunologic and infectious disease research. The image shows a natural killer cell, a type...
